Highlights IceCure Medical Ltd

Equities

ICCM

IL0011224156

Real-time Estimate Cboe BZX Other stock markets 10:03:08 2024-06-10 am EDT			5-day change	1st Jan Change
0.759 ^USD	+0.13%		-26.66%	-28.03%

Jun. 04	FDA to Convene Advisory Panel for Review of IceCure Medical Ltd.'s De Novo Marketing Clearance Request for ProSense®, Decision Expected Early 2025	CI
May. 28	Transcript : IceCure Medical Ltd, Q1 2024 Earnings Call, May 28, 2024

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

FDA to Convene Advisory Panel for Review of IceCure Medical Ltd.'s De Novo Marketing Clearance Request for ProSense®, Decision Expected Early 2025	Jun. 04	CI
Earnings Flash (ICCM) ICECURE MEDICAL Posts Q1 Revenue $743,000, vs. Street Est of $880,000	May. 28	MT
Icecure Medical Ltd. Announces That Positive Data from an Independent Study (The "Study") Performed in Japan Was Published in an Article Titled "Percutaneous Ultrasound?Guided Cryoablation for Early?Stage Primary Breast Cancer: A Follow?Up Study in Japan," in the Journal Breast Cancer on April 27, 2024	May. 07	CI
IceCure Medical Seeks FDA Nod For ProSense to Treat Early-Stage Breast Cancer	Apr. 15	MT
IceCure Medical Ltd Submits Final Data to the U.S. Food and Drug Administration Requesting Marketing Authorization for ProSense	Apr. 15	CI
IceCure Medical Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 03	CI
IceCure Medical Seeks FDA Clearance for Cryoablation Technology	Apr. 02	MT
Icecure Submits FDA Regulatory Filing for New Xsense? Cryoablation System with Cryoprobes	Apr. 02	CI
IceCure Medical Ltd. Reports Positive Topline Results from ICE3 Cryoablation Breast Cancer Study	Mar. 19	CI
IceCure Medical Ltd. Announces Results from an Independent Study	Mar. 04	CI
Icecure Medical Ltd. Announces New Data from A Preliminary, Independent Breast Cancer Study	Feb. 26	CI
Icecure Medical Ltd. Announces U.S. Food and Drug Administration Has Responded Affirmatively to the Company?s Request for Supervisory Review Under 21 Cfr 10.75 Regarding the Fda?S Prior Denial of Icecure?S De Novo Classification Request for Treating Patients with Early-Stage, Low Risk Breast Cancer	Jan. 30	CI
IceCure Medical Regains Nasdaq Compliance	Jan. 12	MT
IceCure Medical Ltd. Announces the Publication of a Study Called "Cryoablation Allows the Ultimate De-Escalation of Surgical Therapy for Select Breast Cancer Patients	Dec. 13	CI
IceCure Medical Ltd. Announces Release of a Study in a Series of Independent Studies of ProSense	Nov. 28	CI
IceCure Medical Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023	Nov. 15	CI
IceCure Medical Files Appeal with U.S. FDA Requesting a Review of its De Novo Classification for ProSense in Early-Stage Breast Cancer	Nov. 15	CI
IceCure Medical Ltd. Announces in Parallel with the Growing Adoption of ProSense(R)	Nov. 06	CI
Icecure Medical Ltd. Announces Provides Update on Substantial Evidence-Based Data Currently Being Generated by 19 Ongoing Studies Using IceCure Medical's Prosense Cryoablation System	Nov. 06	CI
IceCure Medical Receives Minimum Bid Noncompliance Notice From Nasdaq	Nov. 03	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights IceCure Medical Ltd

Equities

ICCM

IL0011224156

Highlights

Filters